The SEC Pulse

ZAG-S&W Represents Pluristem Therapeutics in $17.3 Million Stock Offering

Posted by Leah Schloss on January 27, 2017 at 10:58 AM
Find me on:

A ZAG-S&W team represented Pluristem Therapeutics Inc. (NASDAQCM: PSTI, TASE: PLTR), a leading developer of placenta-based cell therapy products, in its $17.3 million underwritten public offering of common stock and warrants, which included a full exercise of the underwriter’s over-allotment option. Pluristem intends to use the net proceeds of the offering for research and product development activities, clinical trial activities, investment in capital equipment and for working capital and other general corporate purposes.

The offering press releases can be viewed here and here, and the prospectus related to the offering can be found here.

The ZAG-S&W team included Oded Har-Even, Howard Berkenblit, Shy Baranov and Ron Ben-Bassat.


Law firm ZAG-S&W represents U.S. and foreign businesses, as well as sources of equity capital and debt financing such as banks and other financial institutions, individual and institutional investors. The firm facilitates a full range of financing transactions, including: initial public offerings (IPOs), secondary public offerings, venture capital investments, leveraged buyouts, private placements of securities, strategic partnerships and joint ventures. It also regularly handles shelf registrations, periodic SEC filings, stock exchange listings and compliance solutions. "ZAG-S&W's work for clients transcends distance, culture and language," said Oded Har-Even. "Our bilingual team members in Israel and the U.S. understand the dynamics of two very different markets and can deftly bridge cultural differences on business practices, regulatory, securities and other legal issues to achieve your business goals."


Leah Schloss



Topics: SEC, NASDAQ, offering

About the Blog

The SEC Pulse provides updates and commentary from our Capital Markets Group on issues affecting publicly traded and privately owned businesses, investment banks and foreign companies who trade or raise capital in the United States, and boards of directors and company officers in securities transactions and corporate governance matters. 

Meet Howard Berkenblit, SEC Pulse editor


Learn more about our Capital Markets Group


View our Public Company Compliance Manual


Subscribe to Blog

Recent Posts

Posts by Topic

see all